Clinical Trials in Hong Kong

  • Impact of Radiotherapy on ctDNA in Patients With Hepatocellular Carcinoma [Recruiting]

    • Trial period: 8 April 2025 - 31 July 2027
    • Phase: II
    • Sponsor: Chinese University of Hong Kong
    • Responsible party: Dr. Landon Chan, Chinese University of Hong Kong
    Register 

  • Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma [Recruiting]

    • Trial period: 15 February 2023 - 30 June 2026
    • Phase: II
    • Sponsor: The University of Hong Kong
    • Responsible party: The University of Hong Kong, Queen Mary Hospital
    Register 

  • TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma [Recruiting]

    • Trial period: 1 December 2020 - 1 December 2026
    • Phase: II
    • Sponsor: The University of Hong Kong
    • Responsible party: The University of Hong Kong
    Register 

  • Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC [Ending]

    • Trial period: 2 May 2019 - 31 December 2025
    • Phase: III
    • Sponsor: Humanity & Health Medical Group Limited
    • Responsible party: Humanity & Health Medical Group Limited
    Register 

more trials will be announced soon

Helping Patients Understand Clinical Trials and Their Options

A simple guide to clinical trials, the differences between each phase, and how they may offer additional treatment options for eligible patients.

Read More...